Previous 10 | Next 10 |
The study data reinforce the value of TissueCypher in helping physicians and patients make more informed management decisions based on the unique biology of individual patients’ esophageal biopsies Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health th...
Acquisition expands Castle’s estimated U.S. TAM by approximately $5.0 billion to $8.0 billion Castle also announces expanded Medicare coverage for IDgenetix to include seven additional mental health conditions beyond major depressive disorder Castle Bioscience...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2022, after the close of market on Monday, May 9, 2022. Company mana...
In a recent study, patients diagnosed with melanoma and tested with DecisionDx-Melanoma had improved survival (27% improvement in melanoma-specific survival) compared to untested patients Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative ...
Poster presentations to highlight DecisionDx®-Melanoma, DecisionDx®-SCC and Castle’s Comprehensive Diagnostic Offering Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that ...
Skin collection technique shown to be robust with an inter-operator Pearson’s correlation of >0.99 Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a recent poster presentation hig...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the...
Castle Biosciences (CSTL -13.7%) stock slides after brokerage Canaccord lowered its price target to $80 from $94 on the back of the company's M&A announcement. Castle on Monday said it will acquire a commercial-stage molecular diagnostics firm - AltheaDx - for $65M, to expand in...
Castle Biosciences (NASDAQ:CSTL) signs definitive deal on Monday to acquire a commercial-stage molecular diagnostics firm - AltheaDx. The acquisition comes at total consideration of $65M that includes $32.5M cash component and remaining $32.5M in Castle's shares. In addition, a $75M cash...
Furthers mid- and long-term growth with strategic advance into pharmacogenomics and mental health Castle executive management to host conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovat...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...
Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today annou...